Javascript must be enabled to continue!
Clinical impact of the determination of natriuretic peptides on long-term follow-up of patients treated in the Heart Failure Unit
View through CrossRef
Abstract
Introduction
The use of natriuretic peptides has spread in recent years as a diagnostic tool in patients with heart failure (HF). However, its influence on the prognosis of these patients has not been clearly established. Thus, our main aim was to know the characteristics of patients with increased levels of NT-proBNP and to analyze its impact on long-term prognosis in terms of mortality and readmissions due to heart failure.
Material and methods
We selected cases from the heart failure unit at HURS which had a NT-proBNP determination at first consultation. Patients were divided into two groups: GROUP 1 (NT-ProBNP <10000) and GROUP 2 (NT-ProBNP >10000). Clinical, echocardiographic and treatment variables were collected and patients were followed up for readmissions due to heart failure and all-cause mortality.
Results
A total of 280 patients were selected. The mean age of the cohort was 66.74±13.88 years and was male-dominated (64%). In group 1, there was a higher initial left ventricular ejection fraction (LVEF) (43.19% vs 40.36%; p=0.057), lower basal creatinine (1.13 mg/dL vs 1.53 mg/dL; p=0.001), lower creatinine at the end of follow-up (1.27 mg/dL vs 1.79 mg/dL; p=0.001) and a lower NT-proBNP at the end of follow-up (4039 pg/mL vs 17140 pg/mL; p=0.000) than in group 2. In addition, group 2 showed a higher percentage of chronic kidney disease (55% vs 29%; p=0.000) than group 1, with no differences in their main variables. With 110 months of follow-up, patients with NT-proBNP levels>10000 had a similar hospital readmission rate compared to the group with lower NT-proBNP levels (81.2% vs 84.8% log rank p=0.133).With a mean of 130.01±9.11 months of follow-up, patients with NT-proBNP levels>10000 had a tendency to higher mortality from any cause than those with lower NT-proBNP levels (84.4% vs 48.4%, log rank p=0.000).
Conclusion
Patients with NT-proBNP levels>10000 are associated with a lower LVEF at baseline and a higher proportion of chronic kidney disease. In the long term, patients with NT-proBNP levels>10000 had the same rate of readmissions for heart failure but a higher rate of death from any cause.
Kaplan-Meier analysis
Funding Acknowledgement
Type of funding source: None
Oxford University Press (OUP)
Title: Clinical impact of the determination of natriuretic peptides on long-term follow-up of patients treated in the Heart Failure Unit
Description:
Abstract
Introduction
The use of natriuretic peptides has spread in recent years as a diagnostic tool in patients with heart failure (HF).
However, its influence on the prognosis of these patients has not been clearly established.
Thus, our main aim was to know the characteristics of patients with increased levels of NT-proBNP and to analyze its impact on long-term prognosis in terms of mortality and readmissions due to heart failure.
Material and methods
We selected cases from the heart failure unit at HURS which had a NT-proBNP determination at first consultation.
Patients were divided into two groups: GROUP 1 (NT-ProBNP <10000) and GROUP 2 (NT-ProBNP >10000).
Clinical, echocardiographic and treatment variables were collected and patients were followed up for readmissions due to heart failure and all-cause mortality.
Results
A total of 280 patients were selected.
The mean age of the cohort was 66.
74±13.
88 years and was male-dominated (64%).
In group 1, there was a higher initial left ventricular ejection fraction (LVEF) (43.
19% vs 40.
36%; p=0.
057), lower basal creatinine (1.
13 mg/dL vs 1.
53 mg/dL; p=0.
001), lower creatinine at the end of follow-up (1.
27 mg/dL vs 1.
79 mg/dL; p=0.
001) and a lower NT-proBNP at the end of follow-up (4039 pg/mL vs 17140 pg/mL; p=0.
000) than in group 2.
In addition, group 2 showed a higher percentage of chronic kidney disease (55% vs 29%; p=0.
000) than group 1, with no differences in their main variables.
With 110 months of follow-up, patients with NT-proBNP levels>10000 had a similar hospital readmission rate compared to the group with lower NT-proBNP levels (81.
2% vs 84.
8% log rank p=0.
133).
With a mean of 130.
01±9.
11 months of follow-up, patients with NT-proBNP levels>10000 had a tendency to higher mortality from any cause than those with lower NT-proBNP levels (84.
4% vs 48.
4%, log rank p=0.
000).
Conclusion
Patients with NT-proBNP levels>10000 are associated with a lower LVEF at baseline and a higher proportion of chronic kidney disease.
In the long term, patients with NT-proBNP levels>10000 had the same rate of readmissions for heart failure but a higher rate of death from any cause.
Kaplan-Meier analysis
Funding Acknowledgement
Type of funding source: None.
Related Results
Measurement and significance of circulating natriuretic peptides in cardiovascular disease
Measurement and significance of circulating natriuretic peptides in cardiovascular disease
1.The major cardiovascular and renal actions of α-atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) and the fact that the heart is strategically located to sense...
Molecular Mechanism of Blood Pressure Regulation through the Atrial Natriuretic Peptide
Molecular Mechanism of Blood Pressure Regulation through the Atrial Natriuretic Peptide
Natriuretic peptides, including atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), have cardioprotective effects and regulate ...
CLINICAL SIGNIFICANCE OF NATRIURETIC PEPTIDES (review)
CLINICAL SIGNIFICANCE OF NATRIURETIC PEPTIDES (review)
Natriuretic peptides are widely known for their protective effects against the development of metabolic syndrome and cardiovascular disease. The important role of determining the l...
Association between natriuretic peptides and left atrial structural and functional properties in atrial fibrillation following catheter ablation
Association between natriuretic peptides and left atrial structural and functional properties in atrial fibrillation following catheter ablation
Abstract
Background
Atrial natriuretic peptides (ANP) and brain natriuretic peptides (BNP) are acutely released from the atrial ...
Heart failure monitoring using the wearable cardioverter defibrillator in patients with newly diagnosed heart failure
Heart failure monitoring using the wearable cardioverter defibrillator in patients with newly diagnosed heart failure
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
...
The Effects of Xanthine Oxidase Inhibitors on the Management of Cardiovascular Diseases
The Effects of Xanthine Oxidase Inhibitors on the Management of Cardiovascular Diseases
Cardiovascular diseases (CVDs) are the fastest-growing cause of death around the world, and atherosclerosis plays a major role in the etiology of CVDs. The most recent figures show...
Treatment outcomes and associated factors among chronic ambulatory heart failure patients at Jimma Medical Center, South West Ethiopia: prospective observational study
Treatment outcomes and associated factors among chronic ambulatory heart failure patients at Jimma Medical Center, South West Ethiopia: prospective observational study
Abstract
Background
Heart failure has been one of the major causes of hospitalization across the world. Focusing on the treatment outcomes of ambula...
Physiological and Pathophysiological Effects of C-Type Natriuretic Peptide on the Heart
Physiological and Pathophysiological Effects of C-Type Natriuretic Peptide on the Heart
C-type natriuretic peptide (CNP) is the third member of the natriuretic peptide family. Unlike other members, i.e., atrial natriuretic peptide (ANP) and brain natriuretic peptide (...

